Kala Pharmaceuticals Inc. (KALA)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Kala Pharmaceuticals Statistics
Share Statistics
Kala Pharmaceuticals has 4.61M shares outstanding. The number of shares has increased by 71.18% in one year.
Shares Outstanding | 4.61M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 0.06% |
Owned by Institutions (%) | n/a |
Shares Floating | 3.68M |
Failed to Deliver (FTD) Shares | 39 |
FTD / Avg. Volume | 0.1% |
Short Selling Information
The latest short interest is 37.47K, so 0.81% of the outstanding shares have been sold short.
Short Interest | 37.47K |
Short % of Shares Out | 0.81% |
Short % of Float | 0.99% |
Short Ratio (days to cover) | 1.91 |
Valuation Ratios
The PE ratio is -0.4 and the forward PE ratio is -1.06.
PE Ratio | -0.4 |
Forward PE | -1.06 |
PS Ratio | 0 |
Forward PS | 1.5 |
PB Ratio | 2.27 |
P/FCF Ratio | -0.6 |
PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Kala Pharmaceuticals Inc..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.33, with a Debt / Equity ratio of 4.84.
Current Ratio | 6.33 |
Quick Ratio | 6.33 |
Debt / Equity | 4.84 |
Total Debt / Capitalization | 82.88 |
Cash Flow / Debt | -0.77 |
Interest Coverage | -6.73 |
Financial Efficiency
Return on equity (ROE) is -5.62% and return on capital (ROIC) is -89.34%.
Return on Equity (ROE) | -5.62% |
Return on Assets (ROA) | -0.75% |
Return on Capital (ROIC) | -89.34% |
Revenue Per Employee | 0 |
Profits Per Employee | -981.37K |
Employee Count | 43 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 12.62% in the last 52 weeks. The beta is -2.14, so Kala Pharmaceuticals 's price volatility has been lower than the market average.
Beta | -2.14 |
52-Week Price Change | 12.62% |
50-Day Moving Average | 6.82 |
200-Day Moving Average | 6.44 |
Relative Strength Index (RSI) | 67.77 |
Average Volume (20 Days) | 39.21K |
Income Statement
Revenue | n/a |
Gross Profit | -303.00K |
Operating Income | -39.15M |
Net Income | -42.20M |
EBITDA | -36.08M |
EBIT | n/a |
Earnings Per Share (EPS) | -17.35 |
Balance Sheet
The company has 50.90M in cash and 36.32M in debt, giving a net cash position of 14.57M.
Cash & Cash Equivalents | 50.90M |
Total Debt | 36.32M |
Net Cash | 14.57M |
Retained Earnings | -629.41M |
Total Assets | 54.08M |
Working Capital | 27.41M |
Cash Flow
In the last 12 months, operating cash flow was -27.93M and capital expenditures -610.00K, giving a free cash flow of -28.54M.
Operating Cash Flow | -27.93M |
Capital Expenditures | -610.00K |
Free Cash Flow | -28.54M |
FCF Per Share | -11.73 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
KALA does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -211.33% |
FCF Yield | -75.35% |
Analyst Forecast
The average price target for KALA is $15, which is 82.7% higher than the current price. The consensus rating is "Buy".
Price Target | $15 |
Price Target Difference | 82.7% |
Analyst Consensus | Buy |
Analyst Count | 2 |
Stock Splits
The last stock split was on Oct 21, 2022. It was a backward split with a ratio of 1:50.
Last Split Date | Oct 21, 2022 |
Split Type | backward |
Split Ratio | 1:50 |
Scores
Altman Z-Score | -18.01 |
Piotroski F-Score | 2 |